The Burden of Treatment Failure in Type 2 Diabetes
Response to Brown et al.
- Denise G. Simons-Morton, MD, PHD1,
- Saul Genuth, MD2,
- Robert P. Byington, PHD3,
- Hertzel C. Gerstein, MD, MSC4 and
- William T. Friedewald, MD5
- 1Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
- 2Division of Clinical and Molecular Endocrinology, Case Western Reserve University, Cleveland, Ohio
- 3Department of Public Health Sciences, Wake-Forest University, Winston Salem, North Carolina
- 4Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- 5Departments of Biostatistics and Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
- Address correspondence to Denise G. Simons-Morton, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, 6701 Rockledge Dr., MSC 7936, Room 8130, Bethesda, MD 20892-7936. E-mail: simonsd{at}nhlbi.nih.gov
In the July 2004 issue of Diabetes Care, Brown et al. (1) conclude by stating, “our results strongly suggest that the recommended [HbA1c] threshold for [treatment] action should be 7.0% or lower” and “an even stronger signal would be provided by a treatment threshold of 6.0%, which has proved widely …
